Literature DB >> 8412111

Free radical scavengers prevent intestinal ischemia-reperfusion-mediated cardiac dysfunction.

J W Horton1, D J White.   

Abstract

Our previous studies show that intestinal ischemia impairs cardiac function. This present study examined the contribution of oxygen-derived free radicals to cardiac dysfunction after intestinal ischemia-reperfusion in a rat model of superior mesenteric artery (SMA) occlusion (atraumatic clip for 20 min) and ligation of collateral arcades from the right colic and jejunal arteries. Controls were sham operated (Group 1, n = 10); in Group 2, 20 rats with SMA occlusion were sacrificed 2-5 hr after reperfusion without treatment. Superoxide dismutase (SOD) and catalase, scavengers of oxygen-derived free radicals which have been shown to effectively reduce ischemic injury in several models of traumatic injury, were given as 6000 units/350 g body wt either 1 min after SMA occlusion (Group 3, n = 11) or 2 min after reperfusion (Group 4, n = 10). To examine the contribution of neutrophils as a source of free radicals, additional groups of animals were treated with pentoxifylline (PTX, a methylxanthine derivative which has been shown to decrease neutrophil adherence and aggregation as well as to decrease superoxide production) either 1 min after SMA occlusion (Group 5, n = 10) or 2 min after reperfusion (Group 6, n = 10). Cardiac contractile depression occurred in the untreated ischemic group as indicated by a fall in left ventricular pressure (from 77 +/- 3 to 63 +/- 4 mm Hg, P < 0.01) and +dP/dt max (from 1827 +/- 60 to 1558 +/- 98 mm Hg/sec, P < 0.03) and -dP/dt max (from 1267 +/- 57 to 953 +/- 68 mm Hg/sec, P < 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8412111     DOI: 10.1006/jsre.1993.1141

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  Extrahepatic ischemia-reperfusion injury reduces hepatic oxidative drug metabolism as determined by serial antipyrine clearance.

Authors:  B J Gurley; G W Barone; K Yamashita; S Polston; M Estes; A Harden
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

2.  Burn-induced cardiac dysfunction increases length of stay in pediatric burn patients.

Authors:  Taylor S Howard; Daniel G Hermann; Alexis L McQuitty; Lee C Woodson; George C Kramer; David N Herndon; Paul M Ford; Michael P Kinsky
Journal:  J Burn Care Res       Date:  2013 Jul-Aug       Impact factor: 1.845

3.  Pentoxifylline reduces chronic post-ischaemia pain by alleviating microvascular dysfunction.

Authors:  J Vaigunda Ragavendran; A Laferrière; M Khorashadi; T J Coderre
Journal:  Eur J Pain       Date:  2013-07-31       Impact factor: 3.931

4.  Oxymatrine attenuates intestinal ischemia/reperfusion injury in rats.

Authors:  Jinpeng Zhao; Shoujiang Yu; Liquan Tong; Feng Zhang; Xian Jiang; Shangha Pan; Hongchi Jiang; Xueying Sun
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

5.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

6.  Nitroxide radical attenuates ischaemia/reperfusion injury to the rat small intestine.

Authors:  R Udassin; Y Haskel; A Samuni
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

7.  Tramadol alleviates myocardial injury induced by acute hindlimb ischemia reperfusion in rats.

Authors:  Hamed Ashrafzadeh Takhtfooladi; Adel Haghighi Khiabanian Asl; Mehran Shahzamani; Mohammad Ashrafzadeh Takhtfooladi; Amin Allahverdi; Mohammadreza Khansari
Journal:  Arq Bras Cardiol       Date:  2015-06-02       Impact factor: 2.000

8.  Beneficial effect of pentoxifylline into the testis of rats in an experimental model of unilateral hindlimb ischemia/reperfusion injury.

Authors:  Mohammad Ashrafzadeh Takhtfooladi; Fariborz Moayer; Hamed Ashrafzadeh Takhtfooladi
Journal:  Int Braz J Urol       Date:  2015 May-Jun       Impact factor: 1.541

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.